glp 1 based therapies Incretin axis and incretin-based therapies: GLP-1 is produced by the Upcoming wave of hormone-based therapies

Eight major RCTs of GLP-1RAs have investigated the cardiovascular outcomes, including the ELIXA trial of lixisenatide (250), the EXSCEL trial of exenatide ER (251), the LEARDER trial of liraglutide (252), the SUSTAIN-6 trial of subcutaneous semaglutide (253), the HARMONY trial of albiglutide (228), the REWIND trial of dulaglutide (254), the PIONEER trial of oral semaglutide (255), and the SELECT trial of subcutaneous semaglutide (199)

PMID: 37392810

However, its recommended for those currently working in the fitness industry, as the content focuses on supporting clients using GLP-1 medications

Large cardiovascular outcome trials (e.g., Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER), SUSTAIN) and post-marketing surveillance have not demonstrated an increased incidence of MTC in humans, though long-term pharmacovigilance continues given the rarity of this malignancy [30,62]

High intensity interval training in moderation HIIT has its place, but during a taper it should be the smallest portion of your exercise mix

LPS-induced cardiac dysfunction recovered in DPP-4 deficient rats after treatment with sitagliptin